Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

M. A. Dimopoulos, Alexander Keith Stewart, T. Masszi, I. Spicka, A. Oriol, R. Hájek, L. Rosiñol, D. Siegel, G. G. Mihaylov, V. Goranova-Marinova, P. Rajnics, A. Suvorov, R. Niesvizky, A. Jakubowiak, J. San-Miguel, H. Ludwig, S. Ro, S. Aggarwal, P. Moreau, A. Palumbo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide- dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR) = 0.690; P = 0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide. Treatment with KRd led to a 12-month improvement in median PFS vs Rd after first relapse (HR 0.713) and a 9-month improvement after 2 previous lines of therapy (HR 0.720). Treatment with KRd led to an approximate 8-month improvement vs Rd in median PFS in bortezomib-exposed patients (HR 0.699), a 15-month improvement in thalidomide-exposed patients (HR 0.587) and a 5-month improvement in lenalidomideexposed patients (HR 0.796). Objective response and complete response or better rates were higher with KRd vs Rd, irrespective of previous treatment. KRd had a favorable benefit-risk profile and should be considered an appropriate treatment option for patients with 1 or 2 previous lines of therapy and those previously exposed to bortezomib, thalidomide or lenalidomide.

Original languageEnglish (US)
Article numbere554
JournalBlood Cancer Journal
Volume7
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Multiple Myeloma
Dexamethasone
Thalidomide
Disease-Free Survival
Therapeutics
Implosive Therapy
Proteasome Inhibitors
carfilzomib
lenalidomide
Recurrence
Bortezomib

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment. / Dimopoulos, M. A.; Stewart, Alexander Keith; Masszi, T.; Spicka, I.; Oriol, A.; Hájek, R.; Rosiñol, L.; Siegel, D.; Mihaylov, G. G.; Goranova-Marinova, V.; Rajnics, P.; Suvorov, A.; Niesvizky, R.; Jakubowiak, A.; San-Miguel, J.; Ludwig, H.; Ro, S.; Aggarwal, S.; Moreau, P.; Palumbo, A.

In: Blood Cancer Journal, Vol. 7, No. 4, e554, 01.01.2017.

Research output: Contribution to journalArticle

Dimopoulos, MA, Stewart, AK, Masszi, T, Spicka, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, D, Mihaylov, GG, Goranova-Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, A, San-Miguel, J, Ludwig, H, Ro, S, Aggarwal, S, Moreau, P & Palumbo, A 2017, 'Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment', Blood Cancer Journal, vol. 7, no. 4, e554. https://doi.org/10.1038/bcj.2017.31
Dimopoulos, M. A. ; Stewart, Alexander Keith ; Masszi, T. ; Spicka, I. ; Oriol, A. ; Hájek, R. ; Rosiñol, L. ; Siegel, D. ; Mihaylov, G. G. ; Goranova-Marinova, V. ; Rajnics, P. ; Suvorov, A. ; Niesvizky, R. ; Jakubowiak, A. ; San-Miguel, J. ; Ludwig, H. ; Ro, S. ; Aggarwal, S. ; Moreau, P. ; Palumbo, A. / Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment. In: Blood Cancer Journal. 2017 ; Vol. 7, No. 4.
@article{863f5f4f302843de88ccf1231bc91161,
title = "Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment",
abstract = "Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide- dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR) = 0.690; P = 0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide. Treatment with KRd led to a 12-month improvement in median PFS vs Rd after first relapse (HR 0.713) and a 9-month improvement after 2 previous lines of therapy (HR 0.720). Treatment with KRd led to an approximate 8-month improvement vs Rd in median PFS in bortezomib-exposed patients (HR 0.699), a 15-month improvement in thalidomide-exposed patients (HR 0.587) and a 5-month improvement in lenalidomideexposed patients (HR 0.796). Objective response and complete response or better rates were higher with KRd vs Rd, irrespective of previous treatment. KRd had a favorable benefit-risk profile and should be considered an appropriate treatment option for patients with 1 or 2 previous lines of therapy and those previously exposed to bortezomib, thalidomide or lenalidomide.",
author = "Dimopoulos, {M. A.} and Stewart, {Alexander Keith} and T. Masszi and I. Spicka and A. Oriol and R. H{\'a}jek and L. Rosi{\~n}ol and D. Siegel and Mihaylov, {G. G.} and V. Goranova-Marinova and P. Rajnics and A. Suvorov and R. Niesvizky and A. Jakubowiak and J. San-Miguel and H. Ludwig and S. Ro and S. Aggarwal and P. Moreau and A. Palumbo",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/bcj.2017.31",
language = "English (US)",
volume = "7",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

AU - Dimopoulos, M. A.

AU - Stewart, Alexander Keith

AU - Masszi, T.

AU - Spicka, I.

AU - Oriol, A.

AU - Hájek, R.

AU - Rosiñol, L.

AU - Siegel, D.

AU - Mihaylov, G. G.

AU - Goranova-Marinova, V.

AU - Rajnics, P.

AU - Suvorov, A.

AU - Niesvizky, R.

AU - Jakubowiak, A.

AU - San-Miguel, J.

AU - Ludwig, H.

AU - Ro, S.

AU - Aggarwal, S.

AU - Moreau, P.

AU - Palumbo, A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide- dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR) = 0.690; P = 0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide. Treatment with KRd led to a 12-month improvement in median PFS vs Rd after first relapse (HR 0.713) and a 9-month improvement after 2 previous lines of therapy (HR 0.720). Treatment with KRd led to an approximate 8-month improvement vs Rd in median PFS in bortezomib-exposed patients (HR 0.699), a 15-month improvement in thalidomide-exposed patients (HR 0.587) and a 5-month improvement in lenalidomideexposed patients (HR 0.796). Objective response and complete response or better rates were higher with KRd vs Rd, irrespective of previous treatment. KRd had a favorable benefit-risk profile and should be considered an appropriate treatment option for patients with 1 or 2 previous lines of therapy and those previously exposed to bortezomib, thalidomide or lenalidomide.

AB - Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide- dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR) = 0.690; P = 0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide. Treatment with KRd led to a 12-month improvement in median PFS vs Rd after first relapse (HR 0.713) and a 9-month improvement after 2 previous lines of therapy (HR 0.720). Treatment with KRd led to an approximate 8-month improvement vs Rd in median PFS in bortezomib-exposed patients (HR 0.699), a 15-month improvement in thalidomide-exposed patients (HR 0.587) and a 5-month improvement in lenalidomideexposed patients (HR 0.796). Objective response and complete response or better rates were higher with KRd vs Rd, irrespective of previous treatment. KRd had a favorable benefit-risk profile and should be considered an appropriate treatment option for patients with 1 or 2 previous lines of therapy and those previously exposed to bortezomib, thalidomide or lenalidomide.

UR - http://www.scopus.com/inward/record.url?scp=85024486755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024486755&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.31

DO - 10.1038/bcj.2017.31

M3 - Article

C2 - 28430175

AN - SCOPUS:85024486755

VL - 7

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 4

M1 - e554

ER -